DALLAS, Jan. 12, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring VIVUS Inc. (Nasdaq:VVUS). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/VVUS
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
VIVUS Inc. (VVUS) is a pharmaceutical company focused on the development and commercialization of therapeutic products. The Company's late-stage investigational product pipeline includes Qnexa for treating obesity; avanafil, which is being developed for the treatment of erectile dysfunction; and Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women.
Message Board Search for VVUS: http://www.boardcentral.com/boards/VVUS
In the report, the analyst notes:
"Product revenues from the sale of MUSE in the third quarter of 2009 were $4.3 million, as compared to $4.4 million in the third quarter of 2008. License and other revenue was $115,000 and $21 million in the third quarters of 2009 and 2008, respectively. The third quarter 2008 included the recognition of deferred license revenue from Evamist. ... Total revenue for the third quarter of 2009 was $4.4 million, as compared to $25.5 million for the third quarter of 2008.
"VVUS yesterday announced new data from an analysis of the recently completed phase III study (REVIVE TA-301) of avanafil, an investigational drug candidate for the treatment of erectile dysfunction (ED). Patients who attempted intercourse within 15 minutes of dosing were successful 67%, 69% and 72% of the time on 50, 100 and 200 mg of avanafil, respectively, as compared to 29% of the patients on placebo (p<0.05)."
To read the entire report visit: http://www.beaconequity.com/i/VVUS
See what investors are saying about VVUS at penny stock forum
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.